Fosfomycin demonstrates excellent activity against MRSA resistant to other anti-MRSA drugs

U.S.A.: According to a study published in the Journal of Antimicrobial Chemotherapy, fosfomycin exhibited remarkable efficacy against MRSA as well as isolates with resistance to or diminished response to other anti-MRSA medications such vancomycin, daptomycin, and linezolid.

The rising rates of disease resistance and the scarcity of novel antibiotics to combat these pathogens are causing considerable concern. Fosfomycin is of great relevance in this context because of its efficacy against a variety of these bacteria.

Researchers of this study wanted to assess the efficacy of various combinations of antimicrobial drugs used in the treatment of severe Gram-positive infections, including isolates with reduced sensitivity or resistance to vancomycin, daptomycin, linezolid, and ceftaroline, against a collection of MRSA strains, including isolates.

The MICs of fosfomycin, vancomycin, daptomycin, linezolid, ceftaroline, and cefazolin were determined for this purpose using a technique called broth microdilution testing. Chequerboard broth microdilution testing was used to select isolates for additional assessments in order to ascertain the in vitro synergy between fosfomycin and certain antibacterial drugs. In tests, vancomycin, linezolid, daptomycin, ceftaroline, and cefazolin were combined with fosfomycin.